 |
市場調查報告書
商品編碼
2077923
α放射性物質市場：依放射性核種類型、來源、應用、最終用戶和地區分類。Alpha Emitter Market, by Type of Radionuclide (Radium, Actinium, Lead, Astatine-211, Bismuth-213 and Others), by Source (Natural Sources Artificially Produced Sources ), by Application, by End User and by Region, and By Geography |
||||||
預計到 2026 年，α粒子發射材料市場規模將達到 17.893 億美元，到 2033 年將達到 35.994 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 10.5%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 1,789,300,000 美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 10.50% | 預計金額（2033 年） | 35.994億美元 |
α粒子是由兩個質子和兩個中子緊密結合而成的複合粒子。它們在被稱為α崩壞的放射性崩壞過程中從某些放射性核素的原子核中釋放出來。 α粒子與正常（原子量為4）氦原子的原子核相同，即雙電離氦原子。 α粒子（也稱為α射線）是第一種被發現的核輻射，BETA粒子和γ射線隨後也被發現。與其他類型的核輻射相比，α粒子的速度相對較慢，質量較大。這種粒子的運動速度約為光速的5%至7%，即每秒2000萬米，其質量大約相當於四個質子。由於其極強的電離能力，α粒子無法深入物質內部，幾公分厚的空氣或不到十分之一毫米厚的生物組織就能阻擋它們。 α粒子之所以具有如此高的電離能力，是因為它們帶有兩個正電荷，質量比BETA粒子大，而且速度相對較慢。 α粒子可以在極短的距離內造成多次電離。因此，如果釋放的能量相同，α粒子造成的生物損傷可能遠大於BETA粒子。雖然α粒子無法穿透皮膚表面的正常死細胞層，但它們可以損傷眼角膜。 α粒子輻射通常只有在體內或細胞中已有的原子發生放射性崩壞時才會構成安全隱患。若吸入、攝入或經由傷口進入人體，釋放α粒子的物質尤其危險。
市場動態
各大公司正致力於擴大其治療性放射性同位素的生產設施，預計將為全球α放射性同位素市場在預測期內創造極具吸引力的成長機會。例如，2023年3月1日，製藥公司NorthStar Medical Radioisotopes宣布，其在稀有治療性放射性同位素錒-225的商業化生產和供應方面取得了重大進展。一台客製化的IBA RhodotronTT 300-HE電子束加速器已交付並交付在NorthStar位於美國威斯康辛州貝洛伊特的全新Ac-225生產設施中。作為NorthStar擴建計畫的一部分，這個先進的生產設施將專門用於生產非載體摻雜（nca）的Ac-225，以確保Ac-225能夠擴充性、可靠且環保的方式生產，用於治療癌症和嚴重患者。
本報告的主要特點
- 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
- 本節根據公司概況、產品系列、主要趨勢、財務績效和策略等各種參數，對全球α粒子發射材料市場的主要公司進行介紹。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
- 《全球α粒子發射裝置市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過分析全球α粒子發射材料市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 市場趨勢
- 近期趨勢
- 企業併購與商業合作趨勢
- 技術概述
- 監管趨勢
- PEST分析
第4章：全球α粒子發射市場：依放射性核種類型分類（2021-2033年）
- 概述
- 鐳（Ra-223）
- 錒（Ac-225）
- 鉛（Pb-212）
- 砈-211
- 鉍-213
- 其他
第5章：全球α粒子發射市場：依來源分類（2021-2033年）
- 概述
- 天然放射性核種
- 合成放射性核種
第6章：全球α粒子發射裝置市場：依應用領域分類（2021-2033年）
- 概述
- 骨轉移
- 攝護腺癌
- 神經內分泌腫瘤
- 卵巢癌
- 其他
第7章 全球α粒子發射裝置市場：依最終用戶分類（2021-2033年）
- 概述
- 醫院
- 專科診所
- 診斷中心
- 其他
第8章：全球α粒子發射裝置市場：依地區分類（2021-2033年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國。
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- Actinium Pharmaceutical Inc.
- Alpha Tau Medical Ltd
- Bayer AG
- Bracco
- Cardinal Health
- Eckert & Ziegle
- Fusion Pharmaceuticals
- IBA Worldwide
- NorthStar Medical Radioisotopes（NMR）
- Orano Group
- Viewpoint Molecular Targeting
- RadioMedix
- Telix Pharmaceuticals Limited.
- TerraPower, LLC
- NIOWAVE Inc.
- IONETIX Corporation
第10章
- 分析方法
- 關於 Coherent Market Insights
Alpha Emitter Market is estimated to be valued at USD 1,789.3 Mn in 2026 and is expected to reach USD 3,599.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,789.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.50% | 2033 Value Projection: | USD 3,599.4 Mn |
Alpha particles are composite particles consisting of two protons and two neutrons tightly bound together. They are emitted from the nucleus of some radionuclides during a form of radioactive decay, called alpha-decay. An alpha-particle is identical to the nucleus of a normal (atomic mass four) helium atom i.e. a doubly ionized helium atom. Alpha particles (also termed alpha radiation or alpha rays) was the first nuclear radiation to be discovered, beta particles and gamma rays were identified soon after. Alpha particles are relatively slow and heavy compared with other forms of nuclear radiation. The particles travel at 5 to 7 % of the speed of light or 20,000,000 meters per second and has a mass approximately equivalent to 4 protons. Alpha particles, because they are highly ionizing, are unable to penetrate very far through matter and are brought to rest by a few centimeters of air or less than a tenth of a millimeter of biological tissue. Alpha particles are highly ionizing because of their double positive charge, large mass (compared to a beta particle) and because they are relatively slow. They can cause multiple ionizations within a very small distance. This gives them the potential to do much more biological damage for the same amount of deposited energy. Alpha particles cannot penetrate the normal layer of dead cells on the outside of our skin but can damage the cornea of the eye. Alpha-particle radiation is normally only a safety concern if the radioactive decay occurs from an atom that is already inside the body or a cell. Alpha-particle emitters are particularly dangerous if inhaled, ingested, or if they enter a wound.
Market Dynamics
Leading market players are focused on expanding their therapeutic radioisotope production facilities, which is expected to present attractive growth opportunities for global alpha emitter market, over the forecast period. For instance, on March 01, 2023, NorthStar Medical Radioisotopes, a pharmaceutical company, announced that it has made significant progress in its efforts to offer commercial-scale manufacturing of the rare therapeutic radioisotope actinium-225. A custom-built IBA RhodotronTT 300-HE electron beam accelerator has been delivered to NorthStar's new Ac-225 production facility in Beloit, Wisconsin, U.S. and installed in the building. This cutting-edge facility, which is a part of NorthStar's expansion plan, will be exclusively used to produce non-carrier added (n.c.a.) Ac-225, in order to ensure scalable, dependable, and environmentally preferable production of Ac-225 for the treatment of patients with cancer and other serious diseases.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global alpha emitter market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global alpha emitter market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alpha emitter market
Detailed Segmentation:
- Global Alpha Emitter Market, By Type of Radionuclide (Revenue, USD Mn, 2021 - 2033)
- Radium (Ra-223)
- Actinium (Ac-225)
- Lead (Pb-212)
- Astatine-211
- Bismuth-213
- Others
- Global Alpha Emitter Market, By Source (Revenue, USD Mn, 2021 - 2033)
- Natural Sources
- Uranium-238
- Radium-226
- Artificially Produced Sources
- Plutonium
- Americium
- Curium
- Californium
- Global Alpha Emitter Market, By Application (Revenue, USD Mn, 2021 - 2033)
- Bone Metastases
- Prostate Cancer
- Neuroendocrine Tumors
- Ovarian Cancer
- Others
- Global Alpha Emitter Market, By End User (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Others
- Global Alpha Emitter Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Actinium Pharmaceutical Inc.
- Alpha Tau Medical Ltd
- Bayer AG
- Bracco
- Cardinal Health
- Eckert & Ziegle
- Fusion Pharmaceuticals
- IBA Worldwide
- NorthStar Medical Radioisotopes (NMR)
- Orano Group
- Viewpoint Molecular Targeting
- RadioMedix
- Telix Pharmaceuticals Limited.
- TerraPower, LLC
- NIOWAVE Inc.
- IONETIX Corporation.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type of Radionuclide
- Market Snapshot, By Source
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- PEST Analysis
4. Global Alpha Emitter Market, By Type of Radionuclide of Radionuclide, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Radium (Ra-223)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Actinium (Ac-225)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Lead (Pb-212)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Astatine-211
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Bismuth-213
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Alpha Emitter Market, By Source, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Natural Sources
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Artificially Produced Sources
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Alpha Emitter Market, By Application, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Bone Metastases
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Neuroendocrine Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Ovarian Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Alpha Emitter Market, By End User, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Speciality clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Diagnostic centers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
8. Global Alpha Emitter Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U,K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Radionuclide, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Actinium Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alpha Tau Medical Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bracco
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cardinal Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eckert & Ziegle
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fusion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- IBA Worldwide
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NorthStar Medical Radioisotopes (NMR)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Orano Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Viewpoint Molecular Targeting
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RadioMedix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Telix Pharmaceuticals Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- TerraPower, LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NIOWAVE Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- IONETIX Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
